Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker.
Department of Medical Oncology, Cochin Hospital, AP-HP, Paris Paris Descartes University, CARPEM, Paris.
F
F
Da Silva
Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, Paris Paris Descartes University, Paris UMR8638 CNRS, Faculté de Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France.
A
A
Thomas-Schoemann
Department of Medical Oncology, Cochin Hospital, AP-HP, Paris Paris Descartes University, CARPEM, Paris.
O
O
Huillard
Department of Medical Oncology, Cochin Hospital, AP-HP, Paris Paris Descartes University, CARPEM, Paris.
F
F
Goldwasser
Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, Paris Paris Descartes University, Paris benoit.blanchet@aphp.fr.
B
B
Blanchet
D000368:Aged; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000493:pharmacokinetics*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy; D004347:Drug Interactions / Q000502:physiology; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000175:diagnosis; D007211:Indoles / Q000009:adverse effects* / Q000493:pharmacokinetics*; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D011758:Pyrroles / Q000009:adverse effects* / Q000493:pharmacokinetics*; D000077210:Sunitinib
D002121:Calcium Channel Blockers; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib